EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cell Source's enterprise value is $9.48 Mil.
Cell Source's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $-4.35 Mil. Therefore, Cell Source's EV-to-EBITDA for today is -2.18.
The historical rank and industry rank for Cell Source's EV-to-EBITDA or its related term are showing as below:
CLCS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -29.12 Med: 0 Max: 0.39
Current: -2.18
During the past 11 years, the highest EV-to-EBITDA of Cell Source was 0.39. The lowest was -29.12. And the median was 0.00.
CLCS's EV-to-EBITDA is ranked worse than 100% of 472
companies
in the Biotechnology industry
Industry Median: 9.005
vs CLCS: -2.18
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-23), Cell Source's stock price is $0.0002.
Cell Source's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.170. Therefore, Cell Source's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Cell Source EV-to-EBITDA Historical Data
The historical data trend for Cell Source's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cell Source's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cell Source EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, Cell Source's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cell Source's EV-to-EBITDA falls into.
Cell Source EV-to-EBITDA Calculation
Cell Source's EV-to-EBITDA for today is calculated as:
Cell Source's current Enterprise Value is $9.48 Mil.
Cell Source's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.35 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cell Source (OTCPK:CLCS) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Cell Source's PE Ratio for today is calculated as:
Cell Source's share price for today is $0.0002.
Cell Source's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.170.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Cell Source's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. Its other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched and mismatched organ transplantation.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CLCS has been successfully added to your 